Enzalutamide + NSAA + LHRHA or Surgical Castration

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms

Conditions

Prostatic Neoplasms

Trial Timeline

Mar 1, 2014 โ†’ Jun 30, 2027

About Enzalutamide + NSAA + LHRHA or Surgical Castration

Enzalutamide + NSAA + LHRHA or Surgical Castration is a phase 3 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT02446405. Target conditions include Prostatic Neoplasms.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02446405Phase 3Active

Competing Products

20 competing products in Prostatic Neoplasms

See all competitors